EP Patent

EP1216713A1 — Compositions of estrogen-cyclodextrin complexes

Assigned to Bayer Pharma AG · Expires 2002-06-26 · 24y expired

What this patent protects

Clathrates between cyclodextrin and an estrogen in pharmaceutical compositions conferred an increased stability to said estrogen. The estrogen ethinyl estradiol had an increased resistance to oxidative degradation when part of the inclusion complex as measured at an array of temp…

USPTO Abstract

Clathrates between cyclodextrin and an estrogen in pharmaceutical compositions conferred an increased stability to said estrogen. The estrogen ethinyl estradiol had an increased resistance to oxidative degradation when part of the inclusion complex as measured at an array of temperatures and relative humidity levels. Compositions formulated to limit the amount of oxidants also increased the stability of the estrogen. Pharmaceutical compositions comprising an estrogen for female contraception, hormone replacement therapy, menopause, or acne have longer storage lives and may require less amounts of the active substance.

Drugs covered by this patent

Patent Metadata

Patent number
EP1216713A1
Jurisdiction
EP
Classification
—
Expires
2002-06-26
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.